Sihuan Pharmaceutical Holdings Group Ltd. Share Price

Equities

460

BMG8162K1137

Pharmaceuticals

Market Closed - Hong Kong S.E. 09:08:22 29/04/2024 BST 5-day change 1st Jan Change
0.56 HKD 0.00% Intraday chart for Sihuan Pharmaceutical Holdings Group Ltd. +9.80% -13.85%

Financials

Sales 2024 * 2.73B 378M 2.96B 30.09B Sales 2025 * 3.19B 441M 3.45B 35.08B Capitalization 4.81B 665M 5.2B 52.93B
Net income 2024 * 107M 14.8M 116M 1.18B Net income 2025 * 337M 46.6M 365M 3.71B EV / Sales 2024 * 1.76 x
Net cash position 2024 * - 0 0 0 Net cash position 2025 * - 0 0 0 EV / Sales 2025 * 1.51 x
P/E ratio 2024 *
51.8 x
P/E ratio 2025 *
12.9 x
Employees 2,872
Yield 2024 *
9.65%
Yield 2025 *
9.65%
Free-Float 44.97%
More Fundamentals * Assessed data
Dynamic Chart
Sihuan Pharma Unit Wins Bid to Supply Insulin Products to Chinese Government MT
Sihuan Pharmaceutical Narrows 2023 Loss on Absence of Asset, Investment Impairments MT
Sihuan Pharmaceutical Holdings Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sihuan Pharmaceutical's RF Device Wins Registration Approval in China MT
Sihuan Pharmaceutical Holdings Unit Forms Consortium for Ji Yao Restructuring MT
China Approves Drug Registration for Sihuan Pharmaceutical Unit's Type 2 Diabetes Drug MT
Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets CI
China Includes Four Injectables by Sihuan Pharma Associate in Drug Reimbursement List; Shares Rise 3% MT
China Grants Registration Approval to Sihuan Pharmaceutical's Insulin Products MT
Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes CI
China's Medical Products Administrator Approves Sihuan Pharma Unit's Diabetes Drug MT
National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical CI
China Accepts New Drug Application of Sihuan Pharmaceutical Subsidiary's Breast Cancer Treatment MT
China Accepts New Drug Application for Sihuan Pharmaceutical Unit's Breast Cancer Tablets MT
Sihuan Pharmaceutical Swings to H1 Loss MT
More news
1 week+9.80%
Current month+5.66%
1 month+5.66%
6 months-8.20%
Current year-13.85%
More quotes
1 week
0.51
Extreme 0.51
0.57
1 month
0.50
Extreme 0.5
0.57
Current year
0.49
Extreme 0.49
0.66
1 year
0.49
Extreme 0.49
0.83
3 years
0.49
Extreme 0.49
3.95
5 years
0.49
Extreme 0.49
3.95
10 years
0.49
Extreme 0.49
6.68
More quotes
Managers TitleAgeSince
Founder 60 31/12/00
Director of Finance/CFO 50 -
Chief Operating Officer 65 31/12/06
Members of the board TitleAgeSince
Founder 63 31/12/00
Founder 60 31/12/00
Chief Investment Officer 62 17/05/06
More insiders
Date Price Change Volume
29/04/24 0.56 0.00% 16,353,000
26/04/24 0.56 +3.70% 16,044,000
25/04/24 0.54 +1.89% 7,516,000
24/04/24 0.53 +3.92% 7,475,000
23/04/24 0.51 0.00% 2,144,002

Delayed Quote Hong Kong S.E., April 29, 2024 at 09:08 am

More quotes
Sihuan Pharmaceutical Holdings Group Ltd is a holding company mainly engaged in pharmaceutical manufacturing business. The Company operates three segments. Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetics comprehensive solutions. Innovative Medicine and Other Medicine segment is engaged in the research and development of innovative drugs in the fields of digestion, oncology, non-alcoholic hepatitis, diabetes and complications. The Company also operates Generic Medicine segment.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.56
Average target price
-
Consensus

Annual profits - Rate of surprise